Ortho firms mark end of deferred prosecution agreements
This article was originally published in The Gray Sheet
Executive Summary
All five top orthopedic implant makers emerge from an 18-month period of federal monitoring of compliance policies related to surgeon consulting agreements with no new restrictions attached, the Department of Justice announces March 30. Deferred prosecution agreements entered into by four of the firms - Johnson & Johnson/DePuy, Zimmer, Biomet and Smith & Nephew - in September 2007 have now expired and related anti-kickback charges have been dismissed "as a result of the companies' successful completion" of the program, DoJ says. The firms remain subject to corporate integrity agreements with HHS through September 2012. The fifth manufacturer - Stryker - which was subject to the same reform requirements as its competitors as well as monitoring, also has satisfactorily met the terms of a non-prosecution agreement, Justice notes. The government had accused the firms of using surgeon consulting agreements as inducements for product selection (1"The Gray Sheet" Oct. 1, 2007, p. 3)
You may also be interested in...
Ortho Industry Reaches $311 Mil. Settlement With DoJ On Kickback Charges
Four major hip and knee implant manufacturers will pay the government a total of $311 million to settle anti-kickback claims resulting from a two-year Department of Justice and HHS investigation into the companies' financial relationships with surgeons, the New Jersey U.S. Attorney's office announced Sept. 27
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.